To page body
university of tampere: timo vesikari: studies:
Vaccine Research CenterTampereen yliopisto Vaccine Research Center

Publications

2016

Blazevic V, Malm M, Arinobu D, Lappalainen S, Vesikari T. Rotavirus capsid VP6 protein acts as an adjuvant in vivo for norovirus virus-like particles in a combination vaccine. Hum Vaccin Immunother 2016;12(3):740-8.

Vesikari T, Forsten A, Bianco V, Van der Wielen M, Miller JM.Antibody persistence up to 5 years after vaccination of toddlers and children between 12 months and 10 years of age with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine. Hum Vaccin Immunother 2016;12(1):132-9.

Blazevic V, Malm M, Honkanen H, Knip M, Hyöty H, Vesikari T. Development and maturation of norovirus antibodies in childhood. Microbes Infect 2016;18(4):263-9.

Vesikari T, Wysocki J, Beeslaar J, Eiden J, Jiang Q, Jansen KU, Jones TR, Harris SL, O'Neill RE, York LJ, Perez JL. Immunogenicity, Safety, and Tolerability of Bivalent rLP2086 Meningococcal Group B Vaccine Administered Concomitantly With Diphtheria, Tetanus, and Acellular Pertussis and Inactivated Poliomyelitis Vaccines to Healthy Adolescents. J Pediatric Infect Dis Soc 2016;5(2):180-7.

Vesikari T, Østergaard L, Diez-Domingo J, Wysocki J, Flodmark CE, Beeslaar J, Eiden J, Jiang Q, Jansen KU, Jones TR, Harris SL, O'Neill RE, York LJ, Crowther G, Perez JL. Meningococcal Serogroup B Bivalent rLP2086 Vaccine Elicits Broad and Robust Serum Bactericidal Responses in Healthy Adolescents. J Pediatric Infect Dis Soc 2016;5(2):152-60.

Vesikari T, Forsten A, Seppä I, Kaijalainen T, Puumalainen T, Soininen A, Traskine M, Lommel P, Schoonbroodt S, Hezareh M, Moreira M, Borys D, Schuerman L. Effectiveness of the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D-Conjugated Vaccine (PHiD-CV) Against Carriage and Acute Otitis Media-A Double-Blind Randomized Clinical Trial in Finland. J Pediatric Infect Dis Soc 2016 Apr 28. pii: piw010. [Epub ahead of print]

Esposito S, Bonanni P, Maggi S, Tan L, Ansaldi F, Lopalco PL, Dagan R, Michel JP, van Damme P, Gaillat J, Prymula R, Vesikari T, Mussini C, Frank U, Osterhaus A, Celentano LP, Rossi M, Guercio V, Gavazzi G. Recommended immunization schedules for adults: Clinical practice guidelines by the Escmid Vaccine Study Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAidid). Hum Vaccin Immunother 2016 May 2:1-18. [Epub ahead of print]

Huhti L, Hemming-Harlo M, Vesikari T. Norovirus detection from sera of young children with acute norovirus gastroenteritis. J Clin Virol 2016;79:6-9.

Vesikari T. Success of rotavirus vaccination in Africa. Good news and remaining questions. Lancet Glob Health 2016;4:e76–7.

Tamminen K, Malm M, Vesikari T, Blazevic V. Mucosal Antibodies Induced by Intranasal but Not Intramuscular Immunization Block Norovirus GII.4 Virus-Like Particle Receptor Binding. Viral Immunol 2016;29(5):315-9.

Steele AD, Madhi SA, Cunliffe NA, Vesikari T, Phua KB, Lim FS, Nelson EA, Lau YL, Huang LM, Karkada N, Debrus S, Han HH, Benninghoff B. Incidence of rotavirus gastroenteritis by age in African, Asian and European children: Relevance for timing of rotavirus vaccination. Hum Vaccin Immunother 2016 Jun 3:1-7. [Epub ahead of print]

Silfverdal SA, Icardi G, Vesikari T, Flores SA, Pagnoni MF, Xu J, Liu GF, Stek JE, Boisnard F, Thomas S, Ziani E, Lee AW. A Phase III randomized, double-blind, clinical trial of an investigational hexavalent vaccine given at 2, 4, and 11-12 months . Vaccine 2016 Jun 7. pii: S0264-410X(16)30380-2. doi: 10.1016/j.vaccine. 2016.05.054. [Epub ahead of print]

2015

Vesikari T, Blazevic V. Norovirus vaccine: one step closer. J Infect Dis 2015;211(6):853-5.

Paloniemi M, Lappalainen S, Vesikari T. Commonly circulating human coronaviruses do not have a significant role in the etiology of gastrointestinal infections in hospitalized children. J Clin Virol 2015;62:114-7.

Vesikari T, Van Damme P, Giaquinto C, Dagan R, Guarino A, Szajewska H, Usonis V. Pediatr Infect Dis J 2015;34:635-43.

Blazevic V, Malm M, Vesikari T. Induction of homologous and cross-reactive GII.4-specific blocking antibodies in children after GII.4 New Orleans norovirus infection. J Med Virol 2015;87(10):1656-61.

Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, Levin MJ, McElhaney JE, Poder A, Puig-Barberà J, Vesikari T, Watanabe D, Weckx L, Zahaf T, Heineman TC; ZOE-50 Study Group. Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults.N Engl J Med 2015;28;372(22):2087-96.

Malm M, Tamminen K, Lappalainen S, Uusi-Kerttula H, Vesikari T, Blazevic V. Genotype considerations for virus-like particle based bivalent norovirus vaccine composition. Clin Vaccine Immunol 2015;22(6):656-63

Kosalaraksa P, Mehlsen J, Vesikari T, Forstén A, Helm K, Van Damme P, Joura EA, Ciprero K, Maansson R, Luxembourg A, Sobanjo-Ter Meulen A. An Open-Label, Randomized Study of a 9-Valent Human Papillomavirus Vaccine Given Concomitantly with Diphtheria, Tetanus, Pertussis, and Poliomyelitis Vaccines to Healthy Adolescents 11 to 15 Years of Age. Pediatr Infect Dis J 2015; 34:627-34.

Sobanjo-ter Meulen A, Vesikari T, Malacaman EA, Shapiro SA, Dallas MJ, Hoover PA, McFetridge R, Stek JE, Marchese RD, Hartzel J, Watson WJ, Musey LK. Safety, tolerability and immunogenicity of 15-valent pneumococcal conjugate vaccine in toddlers previously vaccinated with 7-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2015;34:186-94.

Markkula J, Hemming M, Vesikari T. Detection of vaccine-derived rotavirus strains in nonimmunocompromised children up to 3-6 months after RotaTeq® vaccination. Pediatr Infect Dis J 2015;34(3):296-8.

Lappalainen S, Pastor AR, Malm M, López-Guerrero V, Esquivel-Guadarrama F, Palomares LA, Vesikari T, Blazevic V. Protection against live rotavirus challenge in mice induced by parenteral and mucosal delivery of VP6 subunit rotavirus vaccine. Arch Virol 2015;160:2075-8.

Vesikari T, Richardus JH, Berglund J, Korhonen T, Flodmark CE, Lindstrand A, Silfverdal SA, Bambure V, Caplanusi A, Dieussaert I, Roy-Ghanta S, Vaughn DW. Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine in Children 6 Months to 17 Years of Age, Previously Vaccinated with an AS03-Adjuvanted A(H1N1)Pdm09 Vaccine: Two Open-label, Randomized Trials. Pediatr Infect Dis J 2015;34:774-82.

Vesikari T. From rubella to rotavirus, and beyond. Hum Vaccin Immunother 2015;11:1302–5. 

Vesikari T, Brodszki N, van Damme P, Diez-Domingo J, Icardi G, Petersen LK, Tran C, Thomas S, Luxembourg A, Baudin M. A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9-15-Year-Old Girls. Pediatr Infect Dis J 2015;34:992-8.

Vesikari T, Forstén A, Arora A, Tsai T, Clemens R. Influenza vaccination in children primed with MF59(®)-adjuvanted or non-adjuvanted seasonal influenza vaccine. Hum Vaccin Immunother 2015;11:2102-12.

Vesikari T, Prymula R, Merrall E, Kohl I, Toneatto D, Dull PM. Meningococcal serogroup B vaccine (4CMenB): Booster dose in previously vaccinated infants and primary vaccination in toddlers and two-year-old children. Vaccine 2015;33:3850-8.

Blazevic V, Malm M, Salminen M, Oikarinen S, Hyöty H, Veijola R, Vesikari T. Multiple consecutive norovirus infections in the first 2 years of life. Eur J Pediatr. 2015 Jul 9. [Epub ahead of print]

Benoit A, Beran J, Devaster JM, Esen M, Launay O, Leroux-Roels G, McElhaney JE, Oostvogels L, van Essen GA, Gaglani M, Jackson LA, Vesikari T, Legrand C, Tibaldi F, Innis BL, Dewé W. Hemagglutination Inhibition Antibody Titers as a Correlate of Protection Against Seasonal A/H3N2 Influenza Disease. Open Forum Infect Dis 2015;2:ofv067.

Vesikari T. Neonatal rotavirus vaccination making headway. Lancet Infect Dis 2015 Aug 26. pii: S1473-3099(15)00295-9. doi: 10.1016/S1473-3099(15)00295-9. [Epub ahead of print]

Vesikari T, Østergaard L, Diez-Domingo J, Wysocki J, Flodmark CE, Beeslaar J, Eiden J, Jiang Q, Jansen KU, Jones TR, Harris SL, O'Neill RE, York LJ, Crowther G, Perez JL. Meningococcal Serogroup B Bivalent rLP2086 Vaccine Elicits Broad and Robust Serum Bactericidal Responses in Healthy Adolescents. J Pediatric Infect Dis Soc 2015 Aug 4. pii: piv039. [Epub ahead of print].

 

2014

van der Velden MV, Fritz R, Pöllabauer EM, Portsmouth D, Howard MK, Kreil TR, Dvorak T, Fritsch S, Vesikari T, Diez-Domingo J, Richmond P, Lee BW, Kistner O, Ehrlich HJ, Barrett PN, Aichinger G. Safety and Immunogenicity of a Vero Cell Culture-Derived Whole-Virus Influenza A(H5N1) Vaccine in a Pediatric Population. J Infect Dis 2014;209:12-23.

Hemming M, Huhti L, Räsänen S, Salminen M, Vesikari T. Rotavirus Antigenemia in Children is Associated with More Severe Clinical Manifestations of Acute Gastroenteritis. Pediatr Infect Dis J 2014;33(4):366-71.

Hemming M, Vesikari T. Detection of Rotateq® Vaccine-Derived Double Reassortant Rotavirus in a 7-Year-Old Child with Acute Gastroenteritis. Pediatr Infect Dis J 2014;33(6):655-6.

Paloniemi M, Lappalainen S, Salminen M, Kätkä M, Kantola K, Hedman L, Hedman K, Söderlund-Venermo M, Vesikari T. Human bocaviruses are commonly found in stools of hospitalized children without causal association to acute gastroenteritis. Eur J Pediatr 2014;173(8):1051-7.

Uusi-Kerttula H, Tamminen K, Malm M, Vesikari T, Blazevic V. Comparison of human saliva and synthetic histo-blood group antigens usage as ligands in norovirus-like particle binding and blocking assays. Microbes Infect 2014;16(6):472-80.

Parez N, Giaquinto C, Du Roure C, Martinon-Torres F, Spoulou V, Van Damme P, Vesikari T. Rotavirus vaccination in Europe: drivers and barriers. Lancet Infect Dis 2014;14(5):416-25.

Lappalainen S, Pastor AR, Tamminen K, López-Guerrero V, Esquivel-Guadarrama F, Palomares LA, Vesikari T, Blazevic V. Immune responses elicited against rotavirus middle layer protein VP6 inhibit viral replication in vitro and in vivo. Hum Vaccin Immunother 2014;10(7):2039–47.

Huhti L, Blazevic V, Puustinen L, Hemming M, Salminen M, Vesikari T. Genetic analyses of norovirus GII.4 variants in Finnish children from 1998 to 2013. Infect Genet Evol 2014 Aug;26:65-71.

Huppertz H, Borte M, Schuster V, Giaquinto C, Vesikari T. Report of the Third European Expert Meeting on Rotavirus Vaccination: Progress in rotavirus universal mass vaccination in Europe. Vaccine 2014;32(34):4243-8.

Matson DO, Vesikari T, Dennehy P, Dallas MD, Goveia MG, Itzler RF, Ciarlet M. Analysis by rotavirus gene 6 reverse transcriptase-polymerase chain reaction assay of rotavirus-positive gastroenteritis cases observed during the vaccination phase of the Rotavirus Efficacy and Safety Trial (REST). Hum Vaccin Immunother 2014;10(8):226–75.

Malm M, Uusi-Kerttula H, Vesikari T, Blazevic V. High Serum Levels of Norovirus Genotype-Specific Blocking Antibodies Correlate With Protection From Infection in Children. J Infect Dis 2014;210:1755–62.

Hartwig S, Uhari M, Renko M, Bertet P, Hemming M, Vesikari T. Hospital bed occupancy for rotavirus and all cause acute gastroenteritis in two Finnish hospitals before and after the implementation of the national rotavirus vaccination program with RotaTeq®. BMC Health Serv Res. 2014 Dec 11;14:632.

2013

Tamminen K, Huhti L, Vesikari T, Blazevic V. Pre-existing Immunity to Norovirus GII-4 Virus-Like Particles Does Not Impair de Novo Immune Responses to Norovirus GII-12 Genotype. Viral Immunol 2013;26:167-70.

Hemming M, Räsänen S, Huhti L, Paloniemi M, Salminen M, Vesikari T. Major reduction of rotavirus, but not norovirus, gastroenteritis in children seen in hospital after the introduction of RotaTeq vaccine into the National Immunization Programme in Finland. Eur J Pediatr 2013;172:739-46.

Vesikari T, Esposito S, Prymula R, Ypma E, Kohl I, Toneatto D, Dull P, Kimura A; for the EU Meningococcal B Infant Vaccine Study group. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet 2013;381:825-35.

Vesikari T, Hardt R, Rümke HC, Icardi G, Montero J, Thomas S, Sadorge C, Fiquet A. Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax (®) ) in individuals aged ≥ 70 years: A randomized study of a single dose versus two different two-dose schedules. Hum Vaccin Immunother 2013;9:858-64

Vesikari T, Forstén A, Desole MG, Ferrera G, Caubet M, Mesaros N, Boutriau D. A combined Haemophilus influenzae type B Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when coadministered with diphtheria, tetanus, acellular pertussis hepatitis B-inactivated poliovirus at 3, 5 and 11 months of age: results of an open, randomized, controlled study. Pediatr Infect Dis J 2013;32:521-9.

Huhti L, Tamminen K, Vesikari T, Blazevic V. Characterization and immunogenicity of norovirus capsid-derived virus-like particles purified by anion exchange chromatography. Arch Virol 2013;158:933-42. 

Armah GE, Kapikian AZ, Vesikari T, Cunliffe N, Jacobson RM, Burlington DB, Ruiz LP Jr. Efficacy, immunogenicity, and safety of two doses of a tetravalent rotavirus vaccine RRV-TV in Ghana with the first dose administered during the neonatal period. J Infect Dis 2013;208:423-31.

Lappalainen S, Tamminen K, Vesikari T, Blazevic V. Comparative immunogenicity in mice of rotavirus VP6 tubular structures and virus-like particles. Hum Vaccin Immunother. 2013;9:1991-2001.

Hemming M, Vesikari T. Genetic diversity of G1P[8] rotavirus VP7 and VP8* antigens in Finland over a 20-year period: No evidence for selection pressure by universal mass vaccination with RotaTeq® vaccine. Infect Genet Evol 2013;19:51-8.

Vesikari T. Intussusception after human rotavirus vaccine. Pediatr Infect Dis J 2013;32:579-80.

Bonanni P, Gershon A, Gershon M, Kulcsár A, Papaevangelou V, Rentier B, Sadzot-Delvaux C, Usonis V, Vesikari T, Weil-Olivier C, de Winter P, Wutzler P. Primary versus secondary failure after varicella vaccination: implications for interval between 2 doses. Pediatr Infect Dis J. 2013;32:e305-13.

Levin MJ, Schmader KE, Gnann JW, McNeil SA, Vesikari T, Betts RF, Keay S, Stek JE, Bundick ND, Su SC, Zhao Y, Li X, Chan IS, Annunziato PW, Parrino J. Varicella-zoster virus-specific antibody responses in 50-59-year-old recipients of zoster vaccine. J Infect Dis 2013;208:1386-90.

Tamminen K, Lappalainen S, Huhti L, Vesikari T, Blazevic V. Trivalent combination vaccine induces broad heterologous immune responses to norovirus and rotavirus in mice. PLoS One 2013;8:e70409.

Vesikari T, Silfverdal SA, Boisnard F, Thomas S, Mwawasi G, Reynolds D. Randomized, controlled, multicenter study of the immunogenicity and safety of a fully liquid combination diphtheria-tetanus toxoid-five-component acellular pertussis (DTaP5), inactivated poliovirus (IPV), and haemophilus influenzae type b (Hib) vaccine compared with a DTaP3-IPV/Hib vaccine administered at 3, 5, and 12 months of age. Clin Vaccine Immunol 2013;20:1647-53.

Vesikari T, Uhari M, Renko M, Hemming M, Salminen M, Torcel-Pagnon L, Bricout H, Simondon F. Impact and Effectiveness of Rotateq® Vaccine Based on Three Years of Surveillance Following Introduction of a Rotavirus Immunization Program in Finland. Pediatr Infect Dis J 2013;32(12):1365-73.

Vesikari T. Virusrokotteet kansallisessa rokotusohjelmassa – lähitulevaisuuden näkymät. Duodecim.2013;129):2427-33.

 

2012

Tamminen Kirsi, Huhti Leena, Koho Tiia, Lappalainen Suvi, Hytönen Vesa, Vesikari Timo, Blazevic Vesna. A comparison of immunogenicity of norovirus GII-4 virus-like particles and P-particles. Immunology 2012;135:89-9.

Puustinen L, Blazevic V, Huhti L, Szakal ED, Halkosalo A, Salminen M, Vesikari T. Norovirus genotypes in endemic acute gastroenteritis of infants and children in Finland between 1994 and 2007. Artikkelit/Tieteellinen aikakauslehti 2012.

Koho Tiia, Huhti Leena, Blazevic Vesna, Nurminen Kirsi, Butcher Sarah J, Laurinmäki Pasi, Kalkkinen Nisse, Rönnholm Gunilla, Vesikari Timo, Hytönen Vesa P, Kulomaa Markku S. Production and characterization of virus-like particles and the P domain protein of GII.4 norovirus. Journal of Virological Methods 2012;179:1-7.

Lappalainen Suvi, Ylitalo Samuli, Arola Anita, Halkosalo Anne, Räsänen Sirpa, Vesikari Timo. Simultaneous presence of human herpesvirus 6 and adenovirus infections in intestinal intussusception of young children. Acta Paeditrica2012;101:663-70.

Vesikari Timo, Beran Jiri, Durviaux Serge, Stainier Isabelle, Idrissi Mohamed El, Walravens Karl, Devaster Jeanne-Marie. Use of real-time polymerase chain reaction (rtPCR) as a diagnostic tool for influenza infection in a vaccine efficacy trial. Journal of Clinical Virology2012;53:22-28.

Vesikari Timo, Beran Jiri, Durviaux Serge, Stainier Isabelle, Idrissi Mohamed El, Walravens Karl, Devaster Jeanne-Marie. Use of real-time polymerase chain reaction (rtPCR) as a diagnostic tool for influenza infection in a vaccine efficacy trial. Artikkelit/Tieteellinen aikakauslehti 2012.

Giaquinto C, Jackson AE, Vesikari T. Report of the second European expert meeting on rotavirus vaccination. Vaccine 2012;30:2237-44.

Vesikari T, Forstén A, Herbinger KH, Cioppa GD, Beygo J, Borkowski A, Groth N, Bennati M, von Sonnenburg F. Safety and immunogenicity of an MF59®-adjuvanted AH/H5N1 pre-pandemic influenza vaccine in adults and the elderly. Vaccine 2012;30:1388-96.

Vesikari T, Prymula R, Schuster V, Tejedor JC, Cohen R, Bouckenooghe A, Damaso S, Han HH. Efficacy and immunogenicity of live-attenuated human rotavirus vaccine in breast-fed and formula-fed European infants. Pediatr Infect Dis J 2012;31:509-13.

Koho T, Mäntylä T, Laurinmäki P, Huhti L, Butcher SJ, Vesikari T, Kulomaa MS, Hytönen VP. Purification of norovirus-like particles (VLPs) by ion exchange chromatography. J Virol Methods 2012;181:6-11.

Schmader KE, Levin MJ, Gnann JW Jr, NcNeil SA, Vesikari T, Betts RF, Keay S, Stek JE, Bundick ND, Su SC, Zhao Y, Li X, Chan IS, Annunziato PW, Parrino J. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis 2012;54:922-8.

Vesikari T, Block SL, Guerra F, Lattanzi M, Holmes S, Izu A, Gaitatzis N, Hilbert AK, Groth N. Immunogenicity, safety and reactogenicity of a mammalian cell-culture-derived influenza vaccine in healthy children and adolescents three to seventeen years of age. Pediatr Infect Dis J 2012;31:494-500.

Vesikari T, Becker T, Gajdos V, Fiquet A, Thomas S, Richard P, Vaudin M. Immunogenicity and safety of a two-dose regimen of a combined measles, mumps, rubella and varicella live vaccine (ProQuad®) in infants from 9 months of age. Vaccine 2012;30:3082-9.

Risku M, Kätkä M, Lappalainen S, Räsänen S, Vesikari T. Human bocavirus types 1, 2 and 3 in acute gastroenteritis of childhood. Acta Paediatr 2012. Epub ahead of print.

Hemming M, Vesikari T. Vaccine derived human-bovine double reassortant rotavirus in infants with acute gastroenteritis. Pediatr Infect Dis J 2012. Epub ahead of print.

Vesikari T, Forstén A, Desole MG, Ferrera G, Caubet M, Mesaros N, Boutriau D. A Combined Haemophilus influenzae Type b-Neisseria meningitidis Serogroup C-Tetanus Toxoid Conjugate Vaccine (Hib-MenC-TT) is Immunogenic and Well-Tolerated When Co-Administered with DTPa-HBV-IPV at 3, 5, and 11 Months of Age: Results of an Open, Randomized, Controlled Study. [Pediatr Infect Dis J 2012 Nov 28 Epub ahead of print]. J Pediatr Dis J 2013;32(5):521-9.

Vesikari T, Forstén A, Boutriau D, Bianco V, Van der Wielen M, Miller JM. A randomized study to assess the immunogenicity, antibody persistence and safety of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in children aged 2-10 years. Hum Vaccin Immunother 2012;8:1892-903.

Vesikari T, Pepin S, Kusters I, Hoffenbach A, Denis M. Assessment of squalene adjuvanted and non-adjuvanted vaccines against pandemic H1N1 influenza in children 6 months to 17 years of age. Hum Vaccin Immunother 2012;8:1283-92.

van der Velden MV, Aichinger G, Pöllabauer EM, Löw-Baselli A, Fritsch S, Benamara K, Kistner O, Müller M, Zeitlinger M, Kollaritsch H, Vesikari T, Ehrlich HJ, Barrett PN. Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: homologous or heterologous booster response following two dose or single dose priming. Vaccine 2012;30:6127-35.

Vesikari T. Rotavirus vaccination: a concise review. Clin Microbiol Infect 2012;18 Suppl 5:57–63.

Vesikari T, Forstén A, Borkowski A, Gaitatzis N, Banzhoff A, Clemens R. Homologous and heterologous antibody responses to a one-year booster dose of an MF59(®) adjuvanted A/H5N1 pre-pandemic influenza vaccine in pediatric subjects. Hum Vaccin Immunother 2012;8:921-8.

 

2011

Rozenbaum Mark , Mangen Marie-Josee, Giaquinto Carlo, Wilschut Jan, Hak Eelko, Postma Maarten for Consensus Group on Dutch Rotavirus Vaccination (CoRoVa-Group). Cost-effectiveness of rotavirus vaccination in the Netherlands : the results of a consensus model. BMC Public Health 2011;11:1-12.

Dennehy Penelope H, Vesikari Timo, Matson David O, Itzler Robbin F, Dallas MichaelJ, Goveia Michelle, Dinubile Mark J, Heaton Penny M, Ciarlet Max . Efficacy of the pentavalent rotavirus vaccine, RotaTeq® (RV5), between doses of a 3-dose series and with less than 3 doses (incomplete regimen). Human Vaccines2011;7:563-8.

Black Steven, Nicolay Uwe, Vesikari Timo, Knuf Markus, Del Giudice Giuseppe, Della Cioppa Giovanni, Tsai Theodore, Clemens Ralf, Rappuoli Rino. Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatric Infectious Disease Journal2011;30:1081-5.

Lee Andrew W, Vesikari Timo, Gilbert Christopher L, Klopfer Stephanie O, Schödel Florian P, Bhuyan Prakash K. Immunogenicity and safety of a Haemophilus influenzae B (Hib)-hepatitis B vaccine with a modified process hepatitis B component administered with concomitant pneumococcal conjugate vaccine to infants. Artikkelit/Tieteellinen aikakauslehti 2011.

Vesikari Timo, Karvonen Aino, Korhonen Tiina, Karppa Tiina, Sadeharju Karita, Fanic Aurélie, Dieussaert Ilse, Schuerman Lode. Immunogenicity of 10-Valent Pneumococcal Nontypeable Haemophilus Influenzae Protein D Conjugate Vaccine When Administered as Catch-up Vaccination to Children 7 Months to 5 Years of Age. Pediatric Infectious Disease Journal 2011;30:e130-41.


Vesikari T, Karvonen A, Bouckenooghe A, Suryakiran PV, Smolenov I, Han HH. Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 oral suspension (liquid formulation) in Finnish infants. Vaccine2011;29:2079-84.

Puustinen Leena, Blazevic Vesna, Salminen Marjo, Hämäläinen Minna, Räsänen Sirpa, Vesikari Timo. Noroviruses as a major cause of acute gastroenteritis in children in Finland, 2009-2010. Artikkelit/Tieteellinen aikakauslehti 2011.

Räsänen Srpa, Lappalainen Suvi, Salminen Marjo, Huhti Leena, Vesikari Timo. Noroviruses in children seen in a hospital for acute gastroenteritis in Finland. Artikkelit/Tieteellinen aikakauslehti 2011.

Huhti Leena, Szakal Evelin D, Puustinen Leena, Salminen Marjo, Huhtala Heini, Valve Oona, Blazevic Vesna, Vesikari Timo. Norovirus GII-4 causes a more severe gastroenteritis than other noroviruses in young children. Artikkelit/Tieteellinen aikakauslehti 2011.

Blazevic Vesna, Lappalainen Suvi, Nurminen Kirsi, Huhti Leena, Vesikari Timo. Norovirus VLPs and rotavirus VP6 protein as combined vaccine for childhood gastroenteritis. Artikkelit/Tieteellinen aikakauslehti 2011.

Vesikari Timo, Knuf Markus, Wutzler Peter, Karvonen Aino, Kieninger-Baum Dorothee, Schmitt Heinz-Josef, Baehner Frank, Borkowski Astrid, Tsai Theodore F, Clemens Ralf. Oil-in-water emulsion adjuvant with influenza vaccine in young children. New England Journal of Medicine 2011;365:1406-16.

Nurminen K, Blazevic V, Huhti L, Räsänen S, Koho T, Hytönen VP, Vesikari T. Prevalence of norovirus GII-4 antibodies in Finnish children. Julkaisun tyyppi: Artikkelit/Tieteellinen aikakauslehti 2011.

Vesikari Timo, Karvonen Aino, Borrow Ray, Kitchin Nick, Baudin Martine, Thomas Stéphane , Fiquet Anne. Results from a Randomized Clinical Trial of Coadministration of RotaTeq, a Pentavalent Rotavirus Vaccine, and NeisVac-C, a Meningococcal Serogroup C Conjugate Vaccine. Artikkelit/Tieteellinen aikakauslehti 2011.

Räsänen Sirpa, Lappalainen Suvi, Halkosalo Anne, Salminen Marjo, Vesikari Timo. Rotavirus gastroenteritis in Finnish children in 2006-2008, at the introduction of rotavirus vaccination. Scandinavian Journal of Infectious Disease 2011;43:58-63.

Vesikari Timo, Martin Jason C, Liss Charles L, Liska Vladimir, Schödel Florian P, Bhuyan Prakash K. Safety and Immunogenicity of a Modified Process Hepatitis B Vaccine in Healthy Infants
Pediatric Infectious Disease Journal 2011;30:0891-3668.

Vesikari Timo, Karvonen Aino, Bianco Veronique, Van der Wielen Marie, Miller Jacqueline. Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: an open, randomized controlled trial. Vaccine 2011;29:4274-84.

Della Cioppa Giovanni, Vesikari Timo, Sokal Etienne, Lindert Kelly, Nicolay Uwe. Trivalent and quadrivalent MF59(®)-adjuvanted influenza vaccine in young children: a dose- and schedule-finding study. Artikkelit/Tieteellinen aikakauslehti 2011.

2010

Huhti L, Blazevic V, Nurminen K, Koho T, Hytönen VP, Vesikari T. A comparison of methods for purification and concentration of norovirus GII-4 capsid virus-like particles. Archives of Virology 2010;155:1855-8.

Kaikkonen S, Räsänen S, Rämet M, Vesikari T. Aichi virus infection in children with acute gastroenteritis in Finland. Epidemiology and Infection2010;138:1166-71.

Vesikari T, Van Damme P, Lindblad N, Pfletschinger U, Radley D, Ryan D, Vuocolo S, Haupt RM, Guris D. An open-label, randomized, multicenter study of the safety, tolerability, and immunogenicity of quadrivalent human papillomavirus (types 6/11/16/18) vaccine given concomitantly with diphtheria, tetanus, pertussis, and poliomyelitis vaccine in healthy adolescents 11 to 17 years of age. Pediatric Infectious Disease Journal2010;29:314-18.

Nuolivirta K, Koponen P, He Q, Halkosalo A, Korppi M, Vesikari T, Helminen M. Bordetella pertussis infection is common in nonvaccinated infants admitted for bronchiolitis. Pediatr Infect Dis J.2010;29:1013-15.

Frey S, Vesikari T, Szymczakiewicz-Multanowska A, Lattanzi M, Izu A, Groth N, Holmes S. Clinical efficacy of cell culture–derived and egg-derived inactivated subunit influenza vaccines in healthy adults. Clin Infect Dis2010;51:997-1004.

Toumi M, Vesikari T, Giaquinto C. Comment on the contribution by Weycker et al., "Cost of routine immunization of young children against rotavirus infection with Rotarix ® versus RotaTeq®".Vaccine 2010;28:7241.

Risku M, Lappalainen S, Räsänen S, Vesikari T. Detection of human coronaviruses in children with acute gastroenteritis. Journal of Clinical Virology2010;48:27-30.

Vesikari T, Karvonen A, Ferrante SA, Ciarlet M. Efficacy of the pentavalent rotavirus vaccine, RotaTeq®, in Finnish infants up to 3 years of age: the Finnish Extension Study. Journal of Clinical Eur J Pediatr 2010;169:1379-86.

Vesikari T, Karvonen A, Tilman S, Borkowski A, Montomoli E, Banzhoff A, Clemens R. Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence. Artikkelit/Tieteellinen aikakauslehti 2010

Vesikari T, Karvonen A, Prymula R, Schuster V, Tejedor JC, Thollot F, Garcia-Corbeira P, Damaso S, Han HH, Bouckenooghe A. Immunogenicity and safety of the human rotavirus vaccine Rotarix co-administered with routine infant vaccines following the vaccination schedules in Europe. Artikkelit/Tieteellinen aikakauslehti 2010.

Lum LC, Borja-Tabora CF, Breiman RF, Vesikari T, Sablan BP, Chay OM, Tantracheewathorn T, Schmitt HJ, Lau YL, Bowonkiratikachorn P, Tam JS, Lee BW, Tan KK, Pejcz J, Cha S, Gutierrez-Brito M, Kaltenis P, Vertruyen A, Czajka H, Bojarskas J, Brooks WA, Cheng SM, Rappaport R, Baker S, Gruber WC, Forrest BD. Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children. Artikkelit/Tieteellinen aikakauslehti 2010.

Zeng SQ, Halkosalo A, Salminen M, Szakal ED, Karvonen A, Vesikari T. Norovirus gastroenteritis in young children receiving human rotavirus vaccine. Scand J Infect Dis 2010;42:540-4.

Vesikari T, Karvonen A, Lindblad N, Korhonen T, Lommel P, Willems P, Dieussaert I, Schuerman L. Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine coadministered with measles-mumps-rubella-varicella vaccine in children aged 12 to 16 months. Pediatric Infectious Disease Journal 2010;29:e47-56.

Vesikari T, Karvonen A, Ferrante SA, Kuter BJ, Ciarlet M. Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine. Artikkelit/Tieteellinen aikakauslehti 2010.

2009

McCormack PL, Keam SJ, Bernstein DI, Grimwood K, Linhares AC, Madhi SA, Nakagomi O, Vesikari T. Rotavirus vaccine RIX4414 (Rotarix): a review of its use in the prevention of rotavirus gastroenteritis. Paediatr Drugs 2009;11:75-88.

Beran J, Vesikari T, Wertzova V, Karvonen A, Honegr K, Lindblad N, Van Belle P, Peeters M, Innis BL, Devaster JM. Efficacy of inactivated split-virus influenza vaccine against culture-confirmed influenza in healthy adults : a prospective, randomized, placebo-controlled trial. Artikkelit/Tieteellinen aikakauslehti 2009.

Vesikari T, Pellegrini M, Karvonen A, Groth N, Borkowski A, O'Hagan DT, Podda A. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatric Infectious Disease Journal 2009;28:563-71.

Nuolivirta K, Hurme M, Halkosalo A, Koponen P, Korppi M, Vesikari T, Helminen M
J. Gene polymorphism of Igng +874 T/A and Tlr4 +896 A/G and recurrent infections and wheezing in toddlers with history of bronchiollitis. The Pediatric Infectious Disease Journal 2009;28:1121-23.

Beran J, Vesikari T, Wertzova V, Karvonen A, Honegr K, Lindblad N, Van Belle P, Peeters M, Innis BL, Devaster JM. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Artikkelit/Tieteellinen aikakauslehti 2009.

Vesikari T, Groth N, Karvonen A, Borkowski A, Pellegrini Mx. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination. Artikkelit/Tieteellinen aikakauslehti 2009.

Vesikari T, Sutherland D, Jackson AE. Report of the 'European Expert Meeting on Rotavirus Vaccination', Tampere, Finland, 19-20 May 2009. Artikkelit/Tieteellinen aikakauslehti 2009.

Vesikari T, Itzler R, Karvonen A, Korhonen T, Van Damme P, Behre U, Bona G, Gothefors L, Heaton PM, Dallas M, Goveia MG. RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe. Artikkelit/Tieteellinen aikakauslehti 2009.

Chevallier B, Vesikari T, Brzostek J, Knuf M, Bermal N, Aristegui J, Borys D, Cleerbout J, Lommel P, Schuerman L. Safety and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines. Pediatric Infectious Disease Journal 2009;28:S109-18.

Van Damme P, Minervini G, Liss CL, McCarson B, Vesikari T, Boslego JW, Bhuyan PK.
Safety, tolerability and immunogenicity of a recombinant hepatitis B vaccine manufactured by a modified process in healthy young adults. Artikkelit/Tieteellinen aikakauslehti 2009.

2008

Ruuskanen O, Peltola H, Vesikari T, toim. Lasten infektiosairaudet. Tampereen yliopiston rokotetutkimuskeskus, 2008.

Vesikari T. Emerging data on the safety and efficacy of influenza vaccines in children. Artikkelit/Tieteellinen aikakauslehti 2008.

Vesikari T. Foreword: ESPID/ESPGHAN Evidence-Based Recommendations for Rotavirus. 2008

Helminen M, Nuolivirta K, Virta M, Halkosalo A, Korppi M, Vesikari T, Hurme M. IL-10 gene polymorphism at - 1082 A/G is associated with severe rhinovirus bronchiolitis in infants. Artikkelit/Tieteellinen aikakauslehti 2008.

Zeng SQ, Halkosalo A, Salminen M, Szakal ED, Puustinen L, Vesikari T. One-step quantitative RT-PCR for the detection of rotavirus in acute gastroenteritis. Artikkelit/Tieteellinen aikakauslehti 2008.

Vesikari T. Rotavirus vaccines. Artikkelit/Tieteellinen aikakauslehti 2008.

Vesikari T, Karvonen A, Smith HM, Dunning A, Razmpour A, Saville MK, Gruber WC, Forrest BD. Safety and tolerability of cold-adapted influenza vaccine, trivalent, in infants younger than 6 months of age. Pediatrics 2008;121:e568-e573.

Gray J, Vesikari T, Van Damme P, Giaquinto C, Mrukowicz J, Guarino A, Dagan R, Szajewska H, Usonis V. Rotavirus. Journal of Pediatric Gastroenterology and Nutrition 2008;46(2):S24-S31.

Mrukowicz J, Szajewska H, Vesikari T. Options for the prevention of rotavirus disease other than vaccination. Journal of Pediatric Gastroenterology and Nutrition 2008;46(2):S32-S37.

Vesikari T, Van Damme P, Giaquinto C, Gray J, Mrukowicz J, Dagan R, Guarino A, Szajewska H, Usonis V. European Society for Paediatric Infectious Diseases / European Society for Paediatric Gastroenterology, Hepatology, and Nutrition Evidence-Based Recommendations for Rotavirus Vaccination in Europe. Journal of Pediatric Gastroenterology and Nutrition 2008;46(2):S38-S48.

Vesikari T, Guarino A. (Guest Editors.) Journal of Paediatric Gastroenterology and Nutrition. 2008;46(2).

Vesikari T. The role of scientific societies in the decision-making process to recommend new vaccines: the example of rotavirus in Europe. Journal of Public Health. 2008;16:287­–290.

2007

Block SL, Vesikari T, Goveia MG, Rivers SB, Adeyi BA, Dallas MJ, Bauder J, Boslego JW, Heaton PM, for the Pentavalent Rotavirus Vaccine Dose Confirmation Efficacy Study Group. Efficacy, Immunogenicity, and Safety of a Pentavalent Human-Bovine (WC3) Reassortant Rotavirus Vaccine at the End of Shelf Life. Pediatrics 2007;1(Vol. 119):11–18.

Belshe RB, Edwards KM, Vesikari T, Black SV, Walker RE, Hultquist M, Kemble G, Connor EM, for the CAIV-T Comparative Efficacy Study Group. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007;356:685–96.

Vesikari T, Baer M, Willems P. Immunogenicity and Safety of a Second Dose of Measles-Mumps-Rubella-Varicella Vaccine in Healthy Children Aged 5 to 6 Years. Pediatr Infect Dis J 2007;26(2):153–158.

Vesikari T, Sadzot-Delvaux C, Rentier B, Gershon A. Increasing Coverage and Efficiency of Measles, Mumps, and Rubella Vaccine and Introducing Universal Varicella Vaccination in Europe: A Role for the Combined Vaccine. Pediatr Infect Dis J 2007;26(7):632–638. 

Vesikari T, Karvonen A, Prymula R, Schuster V, Tejedor JC, Cohen R, Meurice F, Han HH, Damaso S, Bouckenooghe A. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 2007;370:1757-63.

Hibbert CL, Piedra PA, McLaurin KK, Vesikari T, Mauskopf J, Mahadevia PJ. Cost-effectiveness of live-attenuated influenza vaccine, trivalent in preventing influenza in young children attending day-care centres. Vaccine 2007; 25:8010–20.

2006

Soriano-Gabarro M, Mrukowicz J, Vesikari T, Verstraeten T. Burden of rotavirus disease in European Union countries. Pediatr Infect Dis J 2006;25(Suppl):7–11.

Desselberger U, Wolleswinkel-van den Bosch J, Mrukowicz J, Rodrigo C, Giaquinto C, Vesikari T. Rotavirus types in Europe and their significance for vaccination. Pediatr Infect Dis J 2006;25(Suppl):30–41.

Vesikari T, Giaquinto C, Huppertz H-I. Clinical trials of rotavirus vaccines in europe . Pediatr Infect Dis J 2006;25(Suppl):42–7.

Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, Abate H, Breuer T, Clemens SC, Cheuvart B, Espinoza F, Gillard P, Innis BL, Cervantes Y, Linhares AC, Lopez P, Macias-Parra M, Ortega-Barria E, Richardson V, Rivera-Medina DM, Rivera L, Salinas B, Pavia-Ruz N, Salmeron J, Rüttimann R, Tinoco JC, Rubio P, Nunez E, Guerrero ML, Yarzabal JP, Damaso S, Tornieporth N, Saez-Llorens X, Vergara RF, Vesikari T, Bouckenooghe A, Clemens R, De Vos B, O'Ryan M, Human Rotavirus Vaccine Study Group. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006;354:11–22.

Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, Dallas MJ, Heyse JF, Goveia MG, Black SB, Shinefield HR, Christie CD, Ylitalo S, Itzler RF, Coia ML, Onorato MT, Adeyi BA, Marshall GS, Gothefors L, Campens D, Karvonen A, Watt JP, O'Brien KL, DiNubile MJ, Clark HF, Boslego JW, Offit PA, Heaton PM. Rotavirus Efficacy and Safety Trial (REST) Study Team. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006;354:23–33.

Vesikari T, Karvonen A, Forrest BD, Hoshino Y, Chanock RM, Kapikian AZ. Neonatal administration of rhesus rotavirus tetravalent vaccine. Pediatr Infect Dis J 2006;25:118-22.

Vesikari, T. Rotavirusrokote – miksi vasta nyt? Duodecim 2006;122:630–1.

Vesikari, T. Rotavirusrokotteelle on selvä käyttöaihe myös Suomessa. Suom lääk l 2006;61:2242–4.

Vesikari T, Karvonen A, Puustinen L, Szakal ED, Zeng SQ, Delem A, De Vos B. A short report on highlights of world-wide development of RIX4414: An European experience. Vaccine 2006;24:3779.

Vesikari T, Clark HF, Offit PA, Dallas MJ, DiStefano DJ, Goveia MG, Ward RL, Schödel F, Karvonen A, Drummond JE, DiNubile MJ, Heaton PM. Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants. Vaccine 2006;24:4821–9.

Vesikari T, Karvonen A, Korhonen T, Edelman K, Vainionpää R, Salmi A, Saville MK, Cho I, Razmpour A, Rappaport R, O'Neill R, Georgiu A, Gruber W, Mendelman PM, Forrest B, for the CAIV-T Transmission Study Group. A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine. Pediatr Infect Dis J 2006;25:590–5.

Vesikari T, Karvonen AV, Majuri J, Zeng SQ, Pang XL, Kohberger R, Forrest BD, Hoshino Y, Chanock RM, Kapikian AZ. Safety, efficacy, and immunogenicity of 2 doses of bovine-human (UK) and rhesus-rhesus-human rotavirus reassortant tetravalent vaccines in Finnish children. J Infect Dis 2006;194(3):370–76.

The Pediatric ROTavirus European CommitTee (PROTECT). The paediatric burden of rotavirus disease in Europe. Epidemiol Infect 2006;134:908-16.

Vesikari T, Fleming DM, Aristegui JF, Vertruyen A, Ashkenazi S, Rappaport R, Skinner J, Saville MK, Gruber WC, Forrest BD; CAIV-T Pediatric Day Care Clinical Trial Network. Safety, efficacy, and effectiveness of cold-adapted influenza vaccine-trivalent against community-acquired, culture-confirmed influenza in young children attending day care. Pediatrics 2006 ;118:2298-312.

2005

Kondrashova A, Romanov A, Reunanen A, Karvonen A, Viskari H, Vesikari T, Ilonen J, Knip M, Hyöty H. A sixfold gradient in the incidence of type 1 diabetes at the eastern border of Finland - evidence of a critical role of environment in the disease pathogenesis. Ann Med 2005;37:67–72.

Vesikari T, Kortelainen K. MPR-rokotus ja autismi. Mediakohun vaikutus rokotuskattavuuteen Englannissa, Ruotsissa ja Suomessa. Suom Lääk l 2005;60:2487–90.

Viskari H, Ludvigsson J, Uibo R, Salur L, Marciulionyte D, Hermann R, Soltesz G, Fûchtenbusch M, Ziegler A-G, Kondrashova A, Romanov A, Kaplan P, Laron Z, Koskela P, Vesikari T, Huhtala H, Knip M, Hyöty H. - Relationship between the incidence of type 1 diabetes and maternal enterovirus antibodies: time trends and geographical variation. Diabetologia 2005;48:1280–7.

Kapikian AZ, Simonsen L, Vesikari T, Hoshino Y, Morens DM, Chanock RM, La Montagne JR, Murphy BR. A hexavalent human rotavirus-bovine rotavirus ( UK ) reassortant vaccine designed for use in developing countries and delivered in a schedule with the potential to eliminate the risk of intussusception. J Infect Dis 2005;192(Suppl1):S22–9.

Ikegaya H, Zheng HY, Saukko PJ, Varesmaa-Korhonen L, Hovi T, Vesikari T, Suganami H, Takasaka T, Sugimoto C, Ohasi Y, Kitamura T, Yogo Y. Genetic diversity of JC virus in the Saami and the Finns: Implications for their population history. Am J Phys Anthropol 2005;128:185–93.

Vesikari T. Vesirokkorokotus viipyy yhä. Suomen Lääkäril 2005,60:4357.

Rosenfeldt V, Vesikari T, Pang X-L, Zeng S-Q, Tvede M, Paerregaard A. Viral etiology and incidence of acute gastroenteritis in young children attending day-care centers. Pediatr Infect Dis J 2005;24:962–5.

Krohn K, Stanescu I, Blazevic V, Vesikari T, Ranki A, Ustav M. A DNA HIV-1 vaccine based on a fusion gene expressing non-structural and structural genes of consensus sequence of the A–C subtypes and the ancestor sequence of the F–H subtypes. Preclinical and clinical studies. Microbes Infect 2005;7:1405–13.

2004

Vesikari T. Tarvitaanko pneumokokkikonjugaattirokotetta – jos, niin mihin? Suom Lääk l 2004;59:1891.

Vesikari T, Karvonen A, Korhonen T, Espo M, Lebacq E, Forster J, Zepp F, Delem A, De Vos B. Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants. Vaccine 2004;22:2836–42.

De Vos B, Vesikari T, Linhares AC, Salinas B, Perez-Schael I, Ruiz-Palacios GM, Guerrero Mde L, Phua KB, Delem A, Hardt K. A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. Pediatr Infect Dis J 2004;23:S179–82.

Vesikari T, Karvonen A, Puustinen L, Zeng S-Q, Szakal ED, Delem A, De Vos B. Efficacy of RIX4414 Live attenuated human rotavirus vaccine in Finnish infants. Pediatr Infect Dis J 2004;23:937–43.

Vesikari, T. Rotavirusrokotteiden uusi tuleminen. Suom lääk l 2004;59:4251–5.

The older publications (1966-2003) can be found here.

Vanhempia julkaisuja löytyy täältä.

 
Vaccine Research Center
FM 3/Biokatu 10, 33014 University of Tampere
tel. +358 3 355 111
Maintained by: rokotetutkimuskeskus@uta.fi
Last update: 5.9.2016 10.47 Muokkaa